A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 31, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
Phase 2: Percentage of participants with partial response (PR) or complete response (CR) at Week 26
Phase 2: Number of participants with adverse events and clinically significant changes in laboratory parameters, and vital signs to support identification of the RP3D
Phase 2: Plasma concentrations of momelotinib and metabolite of momelotinib 21 (M21) to support identification of the RP3D
Number of flare-free days
Duration of response (DoR)
Show 17 moreShow less
Number of flare-free days with glucocorticoid (GC) dose <=10 mg/day
Percentage of participants achieving complete and partial biochemical response
Objective response rate (ORR) at Week 52
Number of Participants with Hematologic Improvement- Erythroid (HI-E) response per International Working Group (IWG) 2018 criteria
Change from Baseline in Short Form 36 (SF-36) domain and summary scores
Change from Baseline in European Organization for Research and Treatment of Cancer Item Library (EORTC IL) 479 score
Change From Baseline in Patient Reported Outcome Measurement Information System (PROMIS) Physical Function Short Form 10b
Change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-FATIGUE)
Changes from Baseline in Patient Global Impression of Severity (PGIS) scores
Changes in Patient Global Impression of Change (PGIC) scores
Changes from Baseline in European quality of life 5 dimensions 5 level version (EQ-5D-5L)
Changes from Baseline in European quality of life-Visual Analogue Scale (EQ-VAS)
Number of participants with adverse events (AEs) and Serious adverse events (SAEs)
Number of participants with adverse events (AEs) and Serious adverse events (SAEs) by severity
Number of participants with AEs leading to discontinuation or dose modifications
Participants will receive momelotinib at dose level 1 along with glucocorticoids as a background therapy (prednisone or prednisolone). Due to adaptive design of the study, additional participants may be randomized to this arm in phase 3.
Participants will receive momelotinib at dose level 2 along with glucocorticoids as a background therapy (prednisone or prednisolone). Due to adaptive design of the study, additional participants may be randomized to this arm in phase 3
Placebo + GlucocorticoidsPlacebo comparator
Participants will receive momelotinib matched placebo along with glucocorticoids as a background therapy(prednisone or prednisolone). Due to adaptive design of the study, additional participants may be randomized to this arm in phase 3